1. The bioavailability of isoniazid, rifampicin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis;Ellard;Am Rev Respir Dis,1986
2. Acceptability, compliance, and adverse reactions when isoniazid, rifampicin, and pyrazinamide are given as a combined formulation or separately during three-times weekly antituberculosis chemotherapy;Hong Kong Chest Service/British Medical Research Council;Am Rev Respir Dis,1989
3. United States Public Health Service tuberculosis therapy trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide;Geiter;Tubercle Suppl,1987
4. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability;Combs;Ann Int Med,1990
5. Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria;Tubercle,1991